ClinicalTrials.gg
Active, not recruitingNCT06151964CONTEMPOUpdated Oct 23, 2026

A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight

A Phase 1/2 interventional study of AZD9550 and placebo in Overweight and Obesity, sponsored by AstraZeneca. Active, not recruiting at 15 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies in Obesity by AstraZeneca — 8 open to participants now, 12 under way, 5 of them phase 3. Obesity · AstraZeneca.

Enrollment
19th of 50
166 · median 87
Started
2023
with 1 other
Phase 1/2
Only one
of the 52
Primary completion
2027-01
later than 2 of 11 live
Registered
28th of 52
by date

Among the 52 studies in Obesity by AstraZeneca, this one is the 19th largest by enrollment of the 50 interventional ones that give a count, is one of 2 that started in 2023, is the only one in phase 1/2, reaches primary completion later than 2 of the 11 other live ones, and was the 28th registered.

Obesity

11,547 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 52 studies in Obesity by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Obesity by AstraZeneca, or all of them as a file.
02

Study summary

AZD9550, previously being developed for the treatment NASH, is a dual GCG and GLP-1 receptor agonist. AZD9550 is now being developed in combination with AZD6234, a SARA, for the treatment of overweight and obesity and its associated co-morbidities. Co-administration of AZD9550 and AZD6234 is currently being evaluated in participants living with obesity and overweight without T2DM in an ongoing Phase 2b study.

The purpose of this study is to investigate the safety, tolerability, and effects of increasing doses of AZD9550 monotherapy in overweight and obese participants aged 18 through 65 years living with or without T2DM, and to investigate how AZD9550 is absorbed, distributed, and eliminated from the body (Parts A-D).

In addition, the study will investigate the safety and tolerability of co-administration of AZD9550 and AZD6234 in participants living with T2DM with obesity or overweight aged 18 through 75 years (Part E), and safety and tolerability for different titration regimens for AZD9550 in participants living with obesity, but without T2DM, aged 18 through 75 years (Part F).

Read the detailed description

This Phase I/II, randomised, single-blind, placebo-controlled, MAD study will assess the safety and tolerability of AZD9550 monotherapy and co-administration of AZD9550 and AZD6234 and will characterise the PK and PD of AZD9550 monotherapy and co-administration of AZD9550 and AZD6234 following SC administration to overweight and obese participants living with or without T2DM. Inclusion of participants receiving placebo is appropriate for benchmarking the safety and tolerability of AZD9550 and co-administration of AZD9550 and AZD6234. A randomised and single-blind study design has been chosen to minimise bias and includes a placebo to facilitate identification of effects related to the administration of the study intervention rather than the study procedures or situation.

03

Conditions studied

  • Overweight and Obesity

Keywords

  • AZD9550
  • AZD6234
  • Non-alcoholic Fatty Liver Disease
  • Non-alcoholic Steatohepatitis
  • Overweight
  • Obese
  • Obesity
  • Diabetes Mellitus, Type 2
  • Liver Glycogen
  • Adipose Tissue
  • Glucose
  • 3-Hydroxybutyric Acid
  • Subcutaneous Fat
  • Liver fat
  • Magnetic Resonance Imaging
  • Magnetic Resonance Spectroscopy
  • Weight Loss
  • Mixed Meal Tolerance Test
04

In context

Obesity Reclassified

11,547 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 166 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females aged 18 through 65 years (Parts A-D) or 75 years (Part E-F) at the time of screening.
  2. Parts A, B, C only: Participants with or without T2DM. If participants have a diagnosis of T2DM, the glucose control managed with diabetes diet and in addition to metformin treatment no more than two treatment options (with a stable dose 3 months prior to screening).

    Part D only: Participants who are diagnosed with T2DM, have inadequate glycaemic control with diet and exercise. Participants who are prescribed an oral anti-diabetic agent such as metformin, a DPP IV inhibitor, sulphonylurea, glinides, alphaglucosidase inhibitors, and an SGLT2 inhibitor may be eligible to enter the study following a of 4-weeks or 5-half lives (whichever is longer) washout period.

    Part E only: Participants are eligible to be included in the Part E only if they meet all of the following criteria at screening:

    1. Diagnosed with T2DM.
    2. Are treated with diet and exercise only, or any combination of OAD with stable doses in the 3 months prior to dosing.
    3. Participants prescribed a DPP IV inhibitor or a GLP-1RA-containing medicine, alone or in combination with other OADs, may be eligible to enter the study if they have not been treated with any of these drugs for at least 35 days or 5 drug half-lives (whichever is longer) prior to randomisation.
  3. Participants with a screening value within the target range of

    • Parts A to E:≥ 42 to ≤ 86 mmol/mol (6% to 10%).
    • Part F: \< 48 mmol/mol (6.5%).
  4. from ≥ 27 to ≤ 39.9 kg/m2 (inclusive) (Part A-C) or ≥ 27 kg/m2 (Part E), or ≥ 30 kg/m2 (Part F).
  5. use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  6. Written and any locally required authorization (eg, European Union Data Privacy Directive) obtained from the participant prior to performing any protocol-related procedures, including screening evaluations
  7. Ability to complete and meet all eligibility requirements for randomisation within 60 days after signing the ICF.
  8. Venous access suitable for multiple cannulations.
  9. Willing and able to "route of administration" weekly SC injections (Parts C, D, E, and F only).

Exclusion criteria

Exclusion Criteria:

  1. Participants with T2DM (Part F) and participants with T2DM treated with insulin (Parts A-E).
  2. Participants with T2DM treated with more than 3 anti-diabetic therapies (Parts A-D only).
  3. Treatment with GLP-1RA or GLP-1RA/GIPRA within 3 months of screening (Parts A to C only) or within 35 days of randomisation or five half-lives (whichever is shorter) of dosing (Parts E and F only).
  4. History of any disease or disorder which may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
  5. Serum calcitonin suggestive of thyroid C-cell hyperplasia (calcitonin level > 50 ng/L), medullary thyroid carcinoma, or history or family history of multiple endocrine neoplasia at screening.
  6. History or presence of GI, renal, or hepatic disease (with the exception of Gilbert's syndrome), or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs, as judged by the investigator.
  7. History of cancer within the last 10 years, with the exception of non-melanoma skin cancer.
  8. Any clinically important illness (apart from T2DM), as judged by the investigator.
  9. Any medical/surgical procedure, or trauma within 4 weeks prior to screening, at the discretion of the investigator.
  10. Symptoms of insulinopenia or poor blood glucose control (eg, significant thirst, nocturia, polyuria, polydipsia, or weight loss).
  11. Positive or virus serology at screening.
  12. Positive test at screening or participant taking antiretroviral medications as determined by medical history or participant's verbal report.
  13. At screening blood tests, any of the following:

    • ≥ 1.5 ×
    • ALT ≥ 1.5 × ULN
    • TBL ≥ 1.5 × ULN (with the exception of Gilbert's syndrome)
    • below the lower limit of the normal range or any other clinically significant haematological abnormality as judged by the investigator.
    • Total serum calcium, albumin-corrected calcium or ionised calcium \< LLN at screening (Part E).
  14. Impaired renal function defined as ≤ 60 mL/minute/1.73 m2 as defined by Chronic Kidney Disease Epidemiology Collaboration (2021) (Part A to C); or ≤ 45 mL/minute/1.73 m2 (Parts E and F).
  15. Any clinically important abnormalities in clinical chemistry, haematology, coagulation, or urinalysis results other than those specifically described as exclusion criteria herein, as judged by the investigator.
  16. Significant late diabetic complications (macroangiopathy with symptoms of congestive heart disease or peripheral arterial disease, microangiopathy with symptoms of neuropathy, gastroparesis, retinopathy requiring treatment, nephropathy) detected in laboratory results or in clinical history/documentation as judged by the investigator.
  17. Abnormal vital signs, after 10 minutes of supine rest, defined as any of the following:

    • Systolic BP \< 90 mmHg or ≥ 150 mmHg
    • Diastolic BP \< 50 mmHg or ≥ 90 mmHg
    • HR \< 50 or > 85 bpm at resting state
    • Participants may be re-tested for the vital signs criteria only once if, in the investigator's judgement, they are not representative of the participant.
  18. Any clinically important abnormalities in rhythm, conduction, or morphology of the resting and any abnormalities in the 12-lead ECG that, as considered by the investigator, may interfere with the interpretation of changes, including abnormal ST-T-wave morphology or left ventricular hypertrophy.
  19. Participants with implantable cardiac defibrillator or a permanent pacemaker, and participants with symptomatic tachy- or brady-arrhythmias.
  20. Participants with unstable angina pectoris or stable angina pectoris classified higher than Canadian Cardiovascular Society class II or an acute coronary syndrome/acute myocardial infarction or coronary intervention with percutaneous coronary intervention or coronary artery bypass grafting or stroke within 6 months.
  21. In Parts A-D: History of hospitalisation caused by heart failure or a diagnosis of heart failure. In Part E, severe congestive heart failure ( Class III or IV) or recent (\< 6 months) hospitalisation due to heart failure.
  22. Known or suspected history of drug abuse within the past 3 years as judged by the investigator (Parts A-F) and/or a positive screen for drugs of abuse at screening (Parts A-C only).
  23. History of severe allergy/ or ongoing clinically important allergy/hypersensitivity as judged by the investigator.
  24. Whole blood or red blood cell donation, or any blood loss > 500 mL (or > 400 mL in Part D) during the 3 months prior to screening.
  25. History of psychosis or bipolar disorder.
  26. History of major depressive disorder within the 2 years prior to screening or depression, where the participant is deemed to be clinically unstable as judged by the investigator.
  27. Previous hospitalisation for any psychiatric reason.
  28. Questionnaire score ≥ xx within the x years prior to screening or at screening (Parts E and F only).
  29. Received another new chemical entity (defined as a compound that has not been approved for marketing), or has participated in any other clinical study that included drug treatment within at least 30 days or 5 half-lives prior to the first administration of study intervention in this study (whichever is longer). The period of exclusion to begin 30 days or 5 halflives of IMP after the final dose, or after the last visit, whichever is longest. Participants consented and screened, but not randomised into this study or a previous Phase 1 study, are not excluded.
  30. History of lactic acidosis
  31. Use of any of the following medicinal products:

    • Use of systemic within 28 days prior to screening.
    • Use of compounds known to prolong the QTc interval.
    • Use of any herbal preparations or medicinal products licensed for control of body weight or appetite within 3 months prior to screening.
  32. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of study intervention.
  33. Received another new chemical entity (defined as a compound that has not been approved for marketing), or has participated in any other clinical study that included drug treatment within at least 30 days or 5 half-lives prior to the first administration of study intervention in this study (whichever is longer). The period of exclusion to begin 30 days or 5 half-lives of IMP after the final dose, or after the last visit, whichever is longest. Participants consented and screened, but not randomised into this study or previous AZD9550, AZD6234, or AZD9550/AZD6234 combination studies, are not excluded from Part E.
  34. Previous enrolment or randomisation in the present study.
  35. Concurrent participation in another study of any kind is prohibited.
  36. Ongoing weight loss diet (hypocaloric diet) or use of weight loss agents, unless the diet or treatment has been stopped at least 3 months prior to screening and the participant has had a stable body weight (± 5%) during the 3 months prior to screening.
  37. Participants who are vegans, ones with medical dietary restrictions, or participants who are willingly conducting any diet likely to increase ketone levels (Atkins or any similar diet based on increased protein consummation or low carbohydrate content) (Part A-D only).
  38. Excessive intake of caffeine-containing drinks or food (eg, coffee, tea, Coca-Cola/Pepsi or similar drink type, chocolate) as judged by the investigator (Part A-D only).
  39. Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the previous 3 months prior to screening (Part A-D only).
  40. Participants who cannot communicate reliably with the investigator or vulnerable participants (eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order).
  41. The participant is an employee, or close relative of an employee, of AstraZeneca, the Service Provider, or the study site, regardless of the employee's role.
  42. Judgement by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements.
  43. to MRI: such as participants with pacemakers, metallic cardiac valves, magnetic material such as surgical clips, implanted electronic infusion pumps or other conditions that would preclude proximity to a strong magnetic field; participants with history of extreme claustrophobia or participant cannot fit inside the MRI scanner cavity (Parts B and C only).
  44. Serum triglyceride concentrations > 500 mg/dL (5.6 mmol/L) at screening or any other metabolic condition judged by the investigator as likely to precipitate acute pancreatitis (Part E only).
  45. History of use of marijuana or THC-containing products within 3 months prior to screening or unwillingness to abstain from marijuana or THC-containing products use during the study (Parts E and F only).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    Part A: AZD9550

    Multiple repeat doses of AZD9550 given as 4 once weekly SC doses for 4 weeks to 2 sequential cohorts in overweight/obese participants with or without T2DM, evaluating 2 low dose levels of AZD9550

    Drug: AZD9550

  • Experimental
    Part B: AZD9550

    Once weekly up-titration over 5 doses of AZD9550 in overweight/obese participants with or without T2DM

    Drug: AZD9550

  • Experimental
    Part C: AZD9550

    Bi-weekly/monthly up-titration of AZD9550 for 24 weeks in overweight/obese participants with or without T2DM.

    Drug: AZD9550

  • Experimental
    Part D: AZD9550

    Bi-weekly/monthly up-titration of AZD9550 for 24 weeks in overweight/obese Japanese participants with T2DM.

    Drug: AZD9550

  • Experimental
    Part A: placebo

    Multiple repeat doses of placebo given as 4 once weekly SC doses for 4 weeks to 2 sequential cohorts in overweight/obese participants with or without T2DM, evaluating 2 low dose levels of AZD9550

    Drug: placebo

  • Experimental
    Part B: placebo

    Once weekly administration of placebo over 5 doses, volume matched to the active treatment being up-titrated, in overweight/obese participants with or without T2DM

    Drug: placebo

  • Experimental
    Part C: placebo

    Bi-weekly/monthly administration of placebo - volume matched to the active treatment being up-titrated - for 24 weeks in overweight/obese participants with or without T2DM.

    Drug: placebo

  • Experimental
    Part D: placebo

    Bi-weekly/monthly administration of placebo - volume matched to the active treatment being up-titrated - 24 weeks in overweight/obese Japanese participants with T2DM.

    Drug: placebo

  • Experimental
    Part E: AZD9550 and AZD6234

    Bi-weekly/monthly up-titration of AZD9550 and AZD6234 for 24 weeks in overweight/obese participants with T2DM.

    Drug: AZD9550 and AZD6234

  • Experimental
    Part E: placebo

    Bi-weekly/monthly administration of placebo - volume matched to the active treatments being up-titrated - 24 weeks in overweight/obese participants with T2DM.

    Drug: placebo

  • Experimental
    Part F: AZD9550

    Bi-weekly/monthly up-titration of AZD9550 for 28 weeks in obese participants without T2DM.

    Drug: AZD9550

  • Experimental
    Part F: placebo

    Bi-weekly/monthly administration of placebo - volume matched to the active treatment - 28 weeks in obese participants without T2DM.

    Drug: placebo

Interventions

  • Part A: A constant dose Part B: Doses of AZD9550 that increase each week Part C: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks Part D: Doses of AZD9550 that increase every 2 weeks, then every 4 weeks Part F: Doses of AZD9550 that increase every 4 weeks or every 2 weeks and then every 4 weeks

  • Drugplacebo

    Matching administration volumes for SC injection. For Part E placebo two injections of two different placebos.

  • DrugAZD9550 and AZD6234

    Part E: Doses of AZD9550 and AZD6234 that increase every 2 weeks, then every 4 weeks

07

What researchers measure

Primary outcomes

  1. Number and percentage of participants with any AE, SAEs, AEs leading to discontinuation of study intervention, AEs with outcome of death, and AEs leading to withdrawal from study.

    Applicable for Parts A, B, C, D, E, F.

    Time frame: Day - 35 to Day 261

  2. Number and percentage of participants with clinically significant changes from baseline in Vital Sign Parameters.

    Applicable for Parts A, B, C, D, E, F.

    Time frame: Day - 35 to Day 261

  3. Number and percentage of participants with clinically significant changes in ECG parameters.

    Applicable for Parts A, B, C, D, E, F.

    Time frame: Day - 35 to Day 261

  4. Number and percentage of participants with clinically significant changes from baseline in Clinical Laboratory Parameters

    Applicable for Parts A, B, C, D, E, F.

    Time frame: Day - 35 to Day 261

  5. Area Under Concentration-Time Curve of AZD9550 following repeat weekly SC doses

    * AUC from 0 to the time of the last measured concentration (AUClast) at first dose and last dose * AUC over a dosing interval (AUCtau) at first dose and last dose. Applicable for Part A.

    Time frame: Day 1 to Day 65

  6. Maximum observed concentration of AZD9550 following repeat weekly SC doses

    • Cmax at first dose and last dose Applicable for Part A.

    Time frame: Day 1 to Day 65

  7. Half life associated with terminal phase elimination rate constant of AZD9550 following repeat weekly SC doses

    • t1/2λz at first dose and last dose Applicable for Part A.

    Time frame: Day 1 to Day 65

  8. Time to maximum observed concentration of AZD9550 following repeat weekly SC doses

    • tmax at first dose and last dose Applicable for Part A.

    Time frame: Day 1 to Day 65

  9. Apparent oral clearance of AZD9550 following repeat weekly SC doses

    • CL/F at first dose and last dose Applicable for Part A.

    Time frame: Day 1 to Day 65

  10. Apparent volume of distribution of AZD9550 following repeat weekly SC doses

    • Vz/F at first dose and last dose Applicable for Part A.

    Time frame: Day 1 to Day 65

  11. Ratio for AUC of AZD9550 following repeat weekly SC doses

    • Rac AUCtau at last dose Applicable for Part A.

    Time frame: Day 1 to Day 65

  12. Ratio for Cmax of AZD9550 following repeat weekly SC doses

    • Rac Cmax at last dose Applicable for Part A.

    Time frame: Day 1 to Day 65

Secondary outcomes

  1. PD effect of AZD9550 on fasting glucose compared to placebo

    • Absolute change in fasting glucose Applicable for Part A.

    Time frame: From baseline to Week 4

  2. PD effect of AZD9550 on fasting lipid profile compared to placebo

    • Absolute and percentage change in total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, and BHB Applicable for Part A.

    Time frame: From baseline to Week 4

  3. Absolute and percentage change in body weight from baseline

    Applicable for Part A.

    Time frame: From baseline to Week 4

  4. Incidence of anti-AZD9550 antibodies

    • Incidence of ADA to AZD9550 Applicable for Part A.

    Time frame: From Day 1 to Day 65

  5. Absolute change in percentage body fat from baseline

    Applicable for Part A.

    Time frame: From baseline to Week 4

  6. PD effect of AZD9550 on fasting glucose compared to placebo

    • Absolute change in fasting glucose Applicable for Part B.

    Time frame: From baseline to Week 5

  7. PD effect of AZD9550 on fasting lipid profile compared to placebo

    • Absolute and percentage change in total cholesterol, high-density lipoprotein, low-density lipoprotein, triglyceride, and BHB Applicable for Part B.

    Time frame: From baseline to Week 5

  8. Effect of AZD9550 on hepatic fat fraction versus placebo at Week 5

    * Change in hepatic fat fraction as measured by MRI-PDFF * Percent change in hepatic fat fraction as measured by MRI-PDFF Applicable for Part B.

    Time frame: From baseline to Week 5

  9. PD effect of AZD9550 on glucose metabolism following an MMTT compared to placebo

    * Percent change in glucose AUC(0-4h) measured by MMTT * Percent change in insulin AUC(0-4h) measured by MMTT * Percent change in c-peptide AUC(0-4h) measured by MMTT Applicable for Part B.

    Time frame: From baseline to Week 5

  10. Area Under concentration-time Curve of AZD9550 following repeat weekly SC doses

    * AUC from 0 to the time of the last measured concentration (AUClast) at the last dose * AUC over a dosing interval (AUCtau) at first dose and last dose Applicable for Part B.

    Time frame: Day 1 to Day 72

  11. Incidence of anti-AZD9550 antibodies

    • Incidence of ADA to AZD9550 Applicable for Part B.

    Time frame: Day 1 to Day 72

  12. PD effect of AZD9550 on fasting glucose compared to placebo

    • Absolute change in fasting glucose Applicable for Parts C and D.

    Time frame: From baseline to Week 24

  13. PD effect of AZD9550 on fasting lipid profile compared to placebo

    • Absolute and percentage change in total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, and BHB Applicable for Parts C and D.

    Time frame: From baseline to Week 24

  14. The effect of AZD9550 on hepatic fat fraction versus placebo after 13 and 24 weeks of treatment

    * Change in hepatic fat fraction as measured by MRI-PDFF * Percent change in hepatic fat fraction as measured by MRI-PDFF Applicable for Part C.

    Time frame: From baseline to Weeks 13 and 24

  15. Effects of AZD9550 compared to placebo on body weight

    * Change in body weight * Percent change in body weight • Proportion of participants achieving ≥ 5% body weight loss • Proportion of participants achieving ≥ 10% body weight loss * Absolute change in percentage body fat Applicable for Parts C and D.

    Time frame: From baseline to Week 24

  16. Change in daily (24 hours) average glucose levels as measured by CGM

    Applicable for Parts C and D.

    Time frame: From baseline to Day 176

  17. Change in fasting hepatic glycogen concentration adjusted for liver volume as measured by MRS

    Applicable for Part C.

    Time frame: From baseline to Weeks 13 and 24

  18. Area Under concentration-time Curve of AZD9550 following repeat weekly SC doses

    * AUC from 0 to the time of the last measured concentration (AUClast) at the first doses of each dose level and the last dose of MTD * AUC over a dosing interval (AUCtau) at the first doses of each dose level and the last dose of MTD Applicable for Parts C and D.

    Time frame: Day 1 to Day 169

  19. Incidence of anti-AZD9550 antibodies

    • Incidence of ADA to AZD9550 Applicable for Parts C and D.

    Time frame: Day 1 to Day 205

  20. Change in daily (24 hours) average glucose levels as measured by CGM

    Applicable for Part A (excluding during 14 days post last dose). Applicable for Part B (excluding from baseline to Week 6 and during 14 days post last dose). Applicable for Parts C and D.

    Time frame: From baseline to Weeks 1, 2, 3, 4, 5, and 6, and during 14 days post last dose

  21. Change in 7-day average glucose levels as measured by CGM

    Applicable for Part A (excluding during 14 days post last dose). Applicable for Part B (excluding from baseline to Week 6 and during 14 days post last dose). Applicable for Parts C and D.

    Time frame: From baseline to Weeks 1, 2, 3, 4, 5, and 6 and during 14 days post last dose

  22. Change in coefficient of variation of glucose levels as measured by CGM over 7 days

    Applicable for Part A (excluding during 14 days post last dose). Applicable for Part B (excluding from baseline to Week 6 and during 14 days post last dose). Applicable for Parts C and D.

    Time frame: From baseline to Weeks 1, 2, 3, 4, 5, and 6, and during 14 days post last dose

  23. Change in percentage time spent in hyperglycaemia (> 140 mg/dL), normoglycaemia (70 -140 mg/dL), and clinically significant hypoglycaemia (< 54 mg/dL) as measured by CGM over 24 hours

    Applicable for Part A (excluding during 14 days post last dose). Applicable for Part B (excluding from baseline to Week 6 and during 14 days post last dose). Applicable for Parts C and D.

    Time frame: From baseline to Weeks 1, 2, 3, 4, 5, and 6, and during 14 days post last dose

  24. Change in percentage time spent in hyperglycaemia (> 140 mg/dL), normoglycaemia (70 -140 mg/dL), and clinically significant hypoglycaemia (< 54 mg/dL) as measured by CGM over 7 days

    Applicable for Part A (excluding during 14 days post last dose). Applicable for Part B (excluding from baseline to Week 6 and during 14 days post last dose). Applicable for Parts C and D.

    Time frame: From baseline to Weeks 1, 2, 3, 4, 5, and 6, and during 14 days post last dose

  25. Change in fasting hepatic glycogen concentration adjusted for liver volume as measured by MRS

    Applicable for Part B.

    Time frame: From baseline to Week 5

  26. Percentage change in fasting hepatic glycogen concentration adjusted for liver volume as measured by MRS

    Applicable for Part B.

    Time frame: From baseline to Week 5

  27. Change in fasting hepatic glycogen concentration unadjusted for liver volume as measured by MRS

    Applicable for Part B.

    Time frame: From baseline to Week 5

  28. Percentage change in fasting hepatic glycogen concentration unadjusted for liver volume as measured by MRS

    Applicable for Part B.

    Time frame: From baseline to Week 5

  29. Change in liver volume as measured by MRI

    Applicable for Part B.

    Time frame: From baseline to Week 5

  30. Absolute change in body weight

    Applicable for Part B.

    Time frame: From baseline to Week 5

  31. Percent change in body weight

    Applicable for Part B.

    Time frame: From baseline to Week 5

  32. Proportion of participants achieving ≥ 5% body weight loss

    Applicable for Part B.

    Time frame: From baseline to Week 5

  33. Proportion of participants achieving ≥ 10% body weight loss

    Applicable for Part B.

    Time frame: From baseline to Week 5

  34. Change in 7-day average glucose levels as measured by CGM

    Applicable for Parts C and D.

    Time frame: From baseline to Day 176

  35. Change in coefficient of variation of glucose levels as measured by CGM over 7 days

    Applicable for Parts C and D.

    Time frame: From baseline to Day 176 and during 14 days post last dose

  36. Change in percentage time spent in hyperglycaemia (> 140 mg/dL), normoglycaemia (70 -140 mg/dL), and clinically significant hypoglycaemia (< 54 mg/dL) as measured by CGM over 24 hours

    Applicable for Parts C and D.

    Time frame: From baseline to Day 176

  37. Change in percentage time spent in hyperglycaemia (> 140 mg/dL), normoglycaemia (70 -140 mg/dL), and clinically significant hypoglycaemia (< 54 mg/dL) as measured by CGM over 7 days

    Applicable for Parts C and D.

    Time frame: From baseline to Day 176 and during 14 days post last dose

  38. Percentage change in fasting hepatic glycogen concentration adjusted for liver volume as measured by MRS

    Applicable for Part C.

    Time frame: From baseline to Weeks 13 and 24

  39. Change in fasting hepatic glycogen concentration unadjusted for liver volume as measured by MRS

    Applicable for Part C.

    Time frame: From baseline to Weeks 13 and 24

  40. Percentage change in fasting hepatic glycogen concentration unadjusted for liver volume as measured by MRS

    Applicable for Part C.

    Time frame: From baseline to Weeks 13 and 24

  41. Change in liver volume, visceral and SC fat as measured by MRI

    Applicable for Part C.

    Time frame: From baseline to Weeks 13 and 24

  42. Anti-AZD9550 antibody titre among participants with positive serum antibodies to AZD9550

    • Titre of ADA to AZD9550 Applicable for Part A.

    Time frame: From Day 1 to 65

  43. Maximum observed concentration of AZD9550 following repeat weekly SC doses

    • Cmax at the last dose Applicable for Part B.

    Time frame: Day to Day 72

  44. Half life associated with terminal phase elimination rate constant of AZD9550 following repeat weekly SC doses

    • t1/2λz at the last dose Applicable for Part B.

    Time frame: Day 1 to Day 72

  45. Time to maximum observed concentration of AZD9550 following repeat weekly SC doses

    • tmax at the last dose Applicable for Part B.

    Time frame: Day 1 to Day 72

  46. Apparent oral clearance of AZD9550 following repeat weekly SC doses

    • CL/F at the last dose Applicable for Part B.

    Time frame: Day 1 to day 72

  47. Apparent volume of distribution of AZD9550 following repeat weekly SC doses

    • Vz/F at the last dose Applicable for Part B.

    Time frame: Day 1 to Day 72

  48. Anti-AZD9550 antibody titre among participants with positive serum antibodies to AZD9550

    • Titre of ADA to AZD9550 Applicable for Part B.

    Time frame: Day 1 to Day 72

  49. Maximum observed concentration of AZD9550 following repeat weekly SC doses

    • Cmax at the first doses of each dose level and the last dose of MTD Applicable for Parts C and D.

    Time frame: Day 1 to Day 169

  50. Half life associated with terminal phase elimination rate constant of AZD9550 following repeat weekly SC doses

    • t1/2λz at the first doses of each dose level and the last dose of MTD Applicable for Parts C and D.

    Time frame: Day 1 to Day 169

  51. Time to maximum observed concentration of AZD9550 following repeat weekly SC doses

    • tmax at the first doses of each dose level and the last dose of MTD Applicable for Parts C and D.

    Time frame: Day 1 to Day 169

  52. Apparent oral clearance of AZD9550 following repeat weekly SC doses

    • CL/F at the first doses of each dose level and the last dose of MTD Applicable for Parts C and D.

    Time frame: Day 1 to Day 169

  53. Apparent volume of distribution of AZD9550 following repeat weekly SC doses

    • Vz/F at the first doses of each dose level and the last dose of MTD Applicable for Parts C and D.

    Time frame: Day 1 to day 169

  54. Anti-AZD9550 antibody titre among participants with positive serum antibodies to AZD9550

    • Titre of ADA to AZD9550 Applicable for Parts C and D.

    Time frame: Day 1 to Day 205

  55. Change in visceral and subcutaneous fat as measured by MRI

    Applicable for Part B.

    Time frame: From baseline to week 5

  56. PD effect of AZD9550 on glucose metabolism compared to placebo

    • Percent change in fasting glucose, fasting insulin, fasting c-peptide, and HbA1c Applicable for Part A.

    Time frame: From baseline to Week 4

  57. PD effect of AZD9550 on glucose metabolism compared to placebo

    • Percent change in fasting glucose, fasting insulin, fasting c-peptide, and HbA1c Applicable for Part B.

    Time frame: From baseline to Week 5

  58. PD effect of AZD9550 on glucose metabolism compared to placebo

    • Percent change in fasting glucose, fasting insulin, fasting c-peptide, and HbA1c Applicable for Parts C and D.

    Time frame: From baseline to Week 24

  59. PD effect of AZD9550 on fasting insulin compared to placebo

    • Absolute change in fasting insulin Applicable for Part A.

    Time frame: From baseline to Week 4

  60. PD effect of AZD9550 on fasting c-peptide compared to placebo

    • Absolute change in fasting c-peptide Applicable for Part A.

    Time frame: From baseline to Week 4

  61. PD effect of AZD9550 on fasting insulin compared to placebo

    • Absolute change in fasting insulin Applicable for Parts C and D.

    Time frame: From baseline to Week 24

  62. PD effect of AZD9550 on fasting c-peptide compared to placebo

    • Absolute change in fasting c-peptide Applicable for Parts C and D.

    Time frame: From baseline to Week 24

  63. PD effect of AZD9550 on fasting insulin compared to placebo

    • Absolute change in fasting insulin Applicable for Part B.

    Time frame: From baseline to Week 5

  64. PD effect of AZD9550 on fasting c-peptide compared to placebo

    • Absolute change in fasting c-peptide Applicable for Part B.

    Time frame: From baseline to Week 5

  65. Absolute change in percentage body fat

    Applicable for Part B.

    Time frame: From baseline to Week 5

  66. PD effect of AZD9550 on glucose metabolism following an MMTT compared to placebo

    * Percent change in glucose AUC(0-4h) measured by MMTT * Percent change in insulin AUC(0-4h) measured by MMTT * Percent change in c-peptide AUC(0-4h) measured by MMTT * Absolute change in fasting glucose, fasting insulin, and fasting c-peptide * Percent change in fasting glucose, fasting insulin, and fasting c-peptide Applicable for Part C.

    Time frame: From baseline to Week 13 and Week 24

  67. PD effect of AZD9550 on HbA1c compared to placebo

    • Absolute change in HbA1c Applicable for Part A.

    Time frame: From baseline to Week 4

  68. PD effect of AZD9550 on HbA1c compared to placebo

    • Absolute change in HbA1c Applicable for Part B.

    Time frame: From baseline to Week 5

  69. PD effect of AZD9550 on HbA1c compared to placebo

    • Absolute change in HbA1c Applicable for Parts C and D.

    Time frame: From baseline to Week 24

  70. Prevalence, incidence, and titres of ADAs to AZD9550 following co administration of AZD9550 and AZD6234

    • To assess the immunogenicity profile of AZD9550 following co administration with AZD6234. Applicable for Part E.

    Time frame: After 24 weeks

  71. Incidence and titre of ADA to AZD9550

    • To evaluate the immunogenicity profile of AZD9550. Applicable for Part F.

    Time frame: Day 1 to Day 261

  72. Change and percent change in body weight

    • To assess the effects of AZD9550 compared to placebo on body weight Applicable for Part F.

    Time frame: From baseline to Week 29

  73. Proportion of participants achieving ≥ 5% body weight loss

    • To assess the effects of AZD9550 compared to placebo on body weight Applicable for Part F.

    Time frame: From baselines to Week 29

  74. Proportion of participants achieving ≥ 10% body weight loss

    • To assess the effects of AZD9550 compared to placebo on body weight Applicable for Part F.

    Time frame: From baseline to Week 29

  75. Prevalence, incidence, and titres of ADAs to AZD6234 following co administration of AZD9550 and AZD6234

    • To assess the immunogenicity profile of AZD6234 following co administration with AZD9550. Applicable for Part E.

    Time frame: After 24 weeks

08

Study locations

15 sites
  • Research Site
    Graz, 8036, Austria
  • Research Site
    Vienna, 1090, Austria
  • Research Site
    Surrey, British Columbia V3T 4G8, Canada
  • Research Site
    Hamilton, Ontario L8L 5G8, Canada
  • Research Site
    Sarnia, Ontario N7T 4X3, Canada
  • Research Site
    Stouffville, Ontario L4A 1H2, Canada
  • Research Site
    Toronto, Ontario M4G 3E8, Canada
  • Research Site
    Sherbrooke, Quebec J1L 0H8, Canada
  • Research Site
    Magdeburg, 39120, Germany
  • Research Site
    Neu-Ulm, 89231, Germany
  • Research Site
    Neuss, 41460, Germany
  • Research Site
    Fukuoka, 812-0025, Japan
  • Research Site
    Shinjuku-ku, 160-0004, Japan
  • Research Site
    Suita-shi, 565-0853, Japan
  • Research Site
    Uppsala, 752 37, Sweden
09

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Jan 2027, 40 months after the start.

Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's planned 40 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2023
First posted
Nov 30, 2023
StartActual
Sep 29, 2023
Primary completionEst.
Jan 29, 2027
CompletionEst.
Jan 29, 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and design details
1 update, last Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Minor edits only
    + 2 other changes: verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06151964
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 30, 2023
Start date
Sep 29, 2023
Primary completion
Jan 29, 2027 (estimated)
Completion
Jan 29, 2027 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD9550

Start the discussion